AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) + Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥50%

Study limitation reported by the research below: “The trial was terminated at a prespecified interim analysis for futility; all reported efficacy comparisons are descriptive and not powered for formal statistical inference.”